Post-mortem Findings in Huntington's Deep Brain Stimulation: A Moving Target Due to Atrophy by Vedam-Mai, Vinata et al.
Case Report



















, Kelly D. Foote
1
& Michael S. Okun
1,2
1Department of Neurosurgery, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA, 2Department of Neurology,
University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA, 3Department of Pathology, University of Florida, Gainesville, FL, USA
Abstract
Background: Deep brain stimulation (DBS) has been shown to be effective for Parkinson’s disease, essential tremor, and primary dystonia. However, mixed results
have been reported in Huntington’s disease (HD).
Case Report: A single case of HD DBS was identified from the University of Florida DBS Brain Tissue Network. The clinical presentation, evolution, surgical
planning, DBS parameters, clinical outcomes, and brain pathological changes are summarized.
Discussion: This case of HD DBS revealed that chorea may improve and be sustained. Minimal histopathological changes were noted around the DBS leads.
Severe atrophy due to HD likely changed the DBS lead position relative to the internal capsule.
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Introduction
Huntington’s disease (HD) is an autosomal dominant, progressive
neurodegenerative disorder characterized by adult onset of symptoms,
including cognitive decline, psychiatric changes, and movement disorders
including but not limited to chorea, dystonia, rigidity, and/or
bradykinesia.1 There is no cure for HD and many therapeutic options
have demonstrated limited efficacy, and some treatments such as
dopamine blocking agents may result in unintended side effects.2,3
Deep brain stimulation (DBS) is a potentially effective surgical treatment
option for select medication-resistant and disabling hyperkinetic HD-
related comorbidities (e.g. severe chorea and ballism).4 We have
previously reported two HD cases treated with DBS.5 The first case
had medication-resistant chorea in which the chorea at rest responded
reasonably well to bilateral internal globus pallidus (GPi) DBS. The
second was a case of young onset HD with familial dystonia who
presented with generalized dystonia and showed a poor response to
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bilateral GPi DBS. We report in this paper the clinical response to long-
term DBS and also the brain histopathological findings from the first case.
Case report
A 33-year-old male presented to our clinic with a 4-year history of
chorea and an extensive family history of HD. Our group has previously
published details of this case.5 Here we summarize the information in order
to put into context our findings. The patient’s speech was minimally
dysarthric, he had involuntary vocalizations, and he was diagnosed with
vocal tics. He had bilateral chorea and ballism of the upper extremities,
clonic movements in the lower extremities, and dystonia in his hands and
legs. He was unable to self-feed, sit without restraint, or interact with his
daughter as a result of his hyperkinetic movements. The patient’s
hyperkinetic movements failed to respond to multiple dopamine antagonists
including Tetrabenazine 25 mg twice a day, which was prescribed to the
patient in 2009, but then discontinued because of a decrease in both
alertness and appetite. It was determined that palliative bilateral GPi DBS
was reasonable given his relatively preserved cognitive function. This
decision was made following consultation with the family and the patient
about their keen desire for amelioration of choreic movements. Bilateral
GPi DBS was performed followed by implantable pulse generator
placement 3 weeks later. At the time of surgery, both DBS leads were
placed a minimum of 2–3 mm from the internal capsule.
Post surgery
The patient developed worsening dysphagia immediately after the
operation, necessitating percutaneous endoscopic gastrostomy tube
placement prior to hospital discharge. His gait worsened; bradykinesia
had worsened but chorea was significantly better and chorea at rest was
completely resolved. The resulting dysphagia and worsening of gait were
probably due to a transient postoperative condition rather than lead
location, since symptoms improved with time and did not worsen after
the DBS device was turned on. The severity of his persistent movement-
induced chorea was significantly reduced in magnitude and ballistic
character. He had increased falls and dragging of his right foot prior to
activation of the DBS device. Following several difficult postoperative
months he improved, except in gait and balance. His follow-up clinical
scores are summarized in Table 1. From our previous work, we
anticipated a mild worsening of motor scores in later years. The mild
worsening of Unified Huntington’s Disease Rating Scale (UHDRS)
motor assessment observed during follow-up could have been expected
due to the natural progression of the disease. Furthermore, the
worsening of chorea at the 3-year follow-up was most likely a result of
the progression of disease because the chorea did not improve when the
DBS device was turned off during clinic visits. Nevertheless, it is
important to note that the symptoms did not return to pre-DBS levels.
Imaging and DBS settings
Postoperative images of the lead locations are shown in Figure 1. GPi
was targeted, and leads were placed approximately 3 mm lateral to the
internal capsule at the most ventral contact and matched microelectrode
mapping. Optimal stimulation parameters were reached at
6 months post-lead implantation. At his 1-year follow-up, settings were
stable with the exception of increasing stimulation frequency. At the
2-year follow-up, chorea was well controlled and no changes were made to
his DBS parameters. During the 3-year follow-up visit because of
worsening of chorea and right lower extremity dystonia, variable contacts,
amplitude, pulse width, and frequencies were assessed, but motor (pulling)
side effects were observed with no additional benefits. DBS settings were
returned to his 1-year settings. At the 4-year follow-up, his DBS settings
were difficult to modify and the patient was no longer able to care for
himself independently due to increased whole-body rigidity. He had
significant weight loss and developed a sacral decubitus ulcer. Despite his
overall clinical decline, his resting chorea suppression remained controlled.
Neuropathology
The patient prospectively consented at the time of DBS implantation
to donate his brain to the UF DBS Brain Tissue Network program. Brain
Table 1. Baseline and post-DBS UHDRS assessments
Pre-DBS 6 mo. 12 mo. 24 mo. 36 mo. 48 mo.
Motor assessment 80 70 75 39 57 58
Chorea subscore 19 15 10 4 6 6
Behavioral assessment
(severity/frequency)
3/3 2/1 7/8 0/0 0/0 0/0
Independence scale 50 50 NA 10 10 10
Functional capacity 4 1 NA 1 1 1
Verbal fluency raw score NA 6 NA 6 2 2
Functional assessment 5 1 1 1 1 1
Abbreviations: DBS, Deep Brain Stimulation; mo., Months; UHDRS, Unified Huntington’s Disease Rating Scale.
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removal was performed within 24 hours of death; the left hemisphere was
frozen for other studies and the right hemisphere was fixed in 10%
formalin for a follow-up histological examination by a certified
neuropathologist (A.T.Y). Samples were taken from the following
regions: rostral caudate nucleus, basal ganglia, thalamus, hippocampus,
frontal cingulate gyrus and corpus callosum, superior temporal gyrus,
midbrain, pons, cerebellum, dentate cerebellum, frontal white matter
with DBS tract defect, GPi with distal lead defect, globus pallidus at the
anterior commissure, right mesial occipital lobe, and hippocampus.
Immunohistochemistry was performed using antibodies to glial fibrillary
acidic protein (GFAP) and ubiquitin. The neuropathological burden was
stratified on the basis of Vonsattel staging.7,8
Gross pathology observations. The cerebral hemisphere revealed
mild widening of the gyri and narrowing of the sulci, particularly in
the frontoparietal region. There was slight disruption of the
cerebral cortex at the site of entry of the DBS lead into the frontal
lobe. A 0.4-cm focus of recent subarachnoid hemorrhage was
located in the mesial occipital pole adjacent to the primary visual
cortex. Serial coronal sections of the cerebral hemispheres revealed
marked atrophy of the entire caudate nucleus, resulting in
significant hydrocephalus ex vacuo and a marked, straight rather
than convex contour of the caudate nucleus, which was atrophied
and located adjacent to the lateral ventricle. A small slightly
discolored slit-like caudate nucleus was identifiable. DBS lead
tracts were followed through serial coronal sections and the distal
lead tips were located in the GPi just above the optic track
bilaterally. The rostral midbrain, pons, and cerebellum did not
reveal any focal lesions.
Microscopic evaluation. Histological examination was performed on
the right hemisphere. The caudate nucleus was markedly atrophic and
had extensive neuronal loss, gliosis, and significant microglial cell
activation. Neuronal loss was also present in the putamen and globus
Figure 1. Microscopic Analysis at the Level of the Tip of the Deep Brain Stimulation Electrode. (A) The tip of the deep brain stimulation (DBS) lead
was placed in the internal globus pallidus (GPi) and was confirmed by postmortem analysis. Progressive atrophy of the GPi resulted in the lead being much closer to
the internal capsule (,1.3 mm) than would be predicted by microelectrode mapping and macrostimulation. (B) The tip of a DBS lead placed in the GPi confirmed
using hematoxylin and eosin. Some gliosis and hemosiderin deposits are also seen. (C) Gliosis surrounding the tip of the DBS lead as demonstrated by glial fibrillary
acidic protein immunohistochemistry. (D) A rim of meningothelial cells near the lead defect as seen by immunohistochemistry using epithelial membrane antigen.
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pallidus, but to a lesser extent. However, reactive astrocytes (GFAP)
were abundant in these nuclei. There were rare eosinophilic
intranuclear inclusions present in the cerebral cortex; however, no
intranuclear ubiquitin-positive inclusions were identified. These
findings were consistent with Vonsattel Grade 3 (of 4) for HD staging,
indicating that approximately 95% of the neurons in the caudate
nucleus were absent. There was focal widening of perivascular spaces
within the putamen but no significant atherosclerosis or other vascular
pathology within the basal ganglia or deep white matter. There was a
single focus of acute, subarachnoid hemorrhage in the right occipital
lobe with abundant hemosiderin-laden macrophages. The cortex
adjacent to the subarachnoid hemorrhage revealed subpial gliosis and
focal hemosiderosis.
The distal lead tip defect of the DBS electrode was located 1.3 mm
from the internal capsule (Figure 2A). There was remote gliosis at the
distal tip of the DBS lead as supported by immunohistochemistry for
GFAP (Figure 2B), and focal hemosiderin deposition (Figure 2B–H&E,
Figure 2C, GFAP). In addition, the lead tip defect was surrounded
Figure 2. Fusion of Magnetic Resonance and Computed Tomography Images Showing the Lead Locations at the Time of Deep Brain
Stimulation Surgery. The deep brain stimulation lead was placed within the internal globus pallidus and was intended to be .2–3 mm away from the internal
capsule. The physiology was confirmed by postoperative imaging.
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with a ‘‘rim’’ of menigothelial/arachnoidal cells as confirmed by
immunohistochemistry for epithelial membrane antigen (Figure 2D).
These menigothelial cells could have been derived from perivascular
spaces of several small deep penetrating blood vessels that were present
near the distal DBS lead tip defect. More proximally along the DBS
lead track, in the deep white matter of the right frontal lobe, there was
gliosis and hemosiderin deposition. The distal lead tip defect and lead
defect in the right frontal white matter show only remote gliosis around
a central cavity.
Discussion
This case is the first report in the literature of long-term clinical
effects in addition to post-mortem analysis of a HD DBS case. Our
patient was followed for several years clinically prior to his death, and
this clinical follow-up adds to the importance of the report. Following
bilateral GPi DBS, his symptoms were reduced by 51% at 24 months
and by 28% at 36 and 48 months as assessed by UHDRS motor
scores, with improvements of 79% at 2 years and 68% at 4 years on
the chorea subscores. Previously, we had reported the clinical features
of this case at 12 months.5 The patient likely manifested symptoms of
disease progression in combination with some minor, stimulation-
induced side effects. However, we believe that the change in lead
position making it closer to the internal capsule was probably not
causing detrimental side effects similar to the effects of the severity of
disease progression. As we move towards increasing patient numbers
for HD DBS, patient counseling regarding the likelihood of no benefit
or worsening of symptoms with disease progression will become an
integral part of treatment.








Present study 1 GPi 48 68%
Zittel et al.19 3 GPi 12–36 40%–58%
Wojtecki et al.28 6 GPi and GPe 6 60%
Gonzalez et al.10 7 GPi 36 58%
Gruber et al.15 1 GPi STN 48 50%
Cislaghi et al.22 1 GPi 48 67%
Lopez-Sendon Moreno et al.20 1 GPi 60 56%
Huys et al.11 1 GPi 12 NA
Velez-Lago et al.5 2 GPi 12 73%
Spielberger et al.21 1 GPi 48 75%
Garcia-Ruiz et al.13 1 GPi 12 NA
Kang et al.23 2 GPi 24 50% and 63%
Groiss et al.18 1 GPi NA NA
Ligot et al.27 5 GPe 12–19 NA
Biolsi et al.14 1 GPi 48 21%
Fasano et al.17 1 GPi 12 77%
Hebb et al.12 1 GPi 12 50%
Fawcett et al.16 1 GPi 4 56%
Moro et al.25 1 GPi 8 64–76%
Abbreviations: DBS, Deep Brain Stimulation; GPe, External Globus Pallidus; GPi, Internal Globus Pallidus; STN, subthalamic nucleus; UHDRS, Unified
Huntington’s Disease Rating Scale
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Improvements in HD-related hyperkinetic choreic and ballistic
movements have been reported by several groups following GPi
DBS.5,10–22 However, several authors have also observed that
GPi DBS-induced improvements may not extend to bradykinesia,
and this issue has recently been cited as an important limitation of GPi
DBS.10,23–25 This is important to consider in patients similar to the one
we have reported. Since our patient was younger than most of the
other case reports, a more severe clinical presentation of chorea and/
or rigid-akinetic syndrome could be expected. In such presentations,
other targets, which we summarized, could be tried. External globus
pallidus (GPe) DBS may, according to the basal ganglia box model,26
modulate integration of motor symptoms in chorea; however, it
remains unknown if GPe DBS will be viable in humans. Two
case series of GPe DBS have been recently published, as shown in
Table 2.27,28 In HD patients, during the resting ‘‘off’’ stimulation state,
corticosubcortical regional cerebral blood flow has been reported as
reduced. In keeping with the basal ganglia thalamocortical circuit
model, GPe stimulation may be able to modulate connectivity and
reduce regional cerebral blood flow in the basal ganglia and cortical
regions.27 Further support for use of GPe DBS is drawn from the
results of a prospective pilot study by Beste et al.,29 which suggested
that GPe stimulation could be regarded as a beneficial treatment,
specifically with respect to improvement of cognitive symptoms in HD;
however, the rationale for this idea remains speculative.
Postmortem neuropathological examination showed severe atrophy in
the caudate nucleus and putamen consistent with the patient’s disease
stage and consistent with HD progression as shown by several recent
studies.30,31 Microscopic observations and measurement of the distance
between the GPi and internal capsule confirmed that when the patient
expired, there was a worrisome smaller than expected distance between
the internal capsule and GPi, as the DBS lead at death was
approximately 1.3 mm away from the internal capsule (Figure 2).
Most DBS practitioners prefer approximately 2–3 mm of spacing
between the GPi and the internal capsule to avoid stimulation-induced
side effects. As globus pallidus atrophy progresses over the course of
HD,30,31 this phenomenon could result in the unintentional realignment
of the DBS lead too close to the internal capsule (,2.0 mm), despite
adequate placement at the time of implantation. These findings support
our previous hypothesis that progressive brain atrophy could affect the
long-term outcome of DBS, lead to side effects, and render programming
more difficult.32 However, remarkably in our case, programming could
be maintained at similar current densities throughout the 4-year course.
It is possible that smarter DBS devices, such as current steering DBS
leads, would be desirable in a situation where atrophy results in increased
proximity of adjacent structures to the intended target, resulting in a
narrower therapeutic stimulation window.33 The ideal DBS system
would facilitate directional sculpting of the electrical field in order to
selectively stimulate the intended target. Novel DBS lead designs may
also be specifically relevant for patients whose DBS leads are placed in
suboptimal locations, and may present an opportunity for better
management of anatomical shifts due to progressive atrophy over time.
In summary, this case revealed that choreic symptoms improve and
remain stable following bilateral GPi DBS with a 4-year follow-up. There
was improvement of resting chorea and stable improvement in outcome at
48 months post implantation. Despite severe atrophy of the GPi, there was
minimal, local histopathological change associated with the DBS device.
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